# Unapproved Product Dossier — editorial working template

> **For drafting only.** This original worksheet aligns to the A section family in AMCP Format 5.0 without reproducing AMCP text. It is not an AMCP form. Use the official Format and internal legal/regulatory/compliance review before any communication.

## Dossier control

| Field | Complete |
|---|---|
| Product / sponsor | |
| Draft version / date / owner | |
| Regulatory status; anticipated milestone(s) | |
| Intended HCDM audience / purpose | |
| Evidence cutoff date | |
| Required status statement confirmed | |
| Link to common instructions / evidence trace / change log | |

**Required drafting discipline:** label information **projected/pending** or **unavailable** where appropriate. Use factual, objective wording. Do not write a value proposition or characterize/conclude on safety or effectiveness for the unapproved product.

## 1.0A — Highlights and overview
- Product and anticipated use: [factual description]
- Development status, key milestones, and uncertainty: 
- Disease burden / anticipated population:
- Anticipated administration, care setting, distribution, and support:
- Projected pricing / access information, basis, range, and uncertainty:
- Unapproved-status limitation:
- Linked evidence IDs:

## 2.0A — Product information and disease description
### 2.1A Product information
| Topic | Draft factual content | Status | Evidence ID |
|---|---|---|---|
| Product / class / mechanism | | | |
| Anticipated indication / population | | | |
| Development program and regulatory milestones | | | |
| Administration / site of care | | | |
| Product-specific operational considerations | | | |

### 2.2A Disease description
| Topic | Draft factual content | Population relevance | Evidence ID |
|---|---|---|---|
| Epidemiology / burden | | | |
| Current treatment pathway and unmet need | | | |
| Equity / access considerations | | | |

## 3.0A — Clinical evidence
| Study / source | Design and status | Population / comparator | Endpoint and result | Material limitation | Evidence ID |
|---|---|---|---|---|---|

- Study synthesis and remaining evidence gaps:
- Planned / ongoing studies (clearly labeled):
- RWE availability, data fitness, and protocol status:
- ITC/NMA: network scope, assumptions, certainty, and limits:

## 4.0A — Economic information
| Topic | Input / assumption | Projected status and basis | Sensitivity / uncertainty | Evidence ID |
|---|---|---|---|---|
| Anticipated acquisition / administration costs | | | | |
| Resource use and site-of-care assumptions | | | | |
| Expected budget considerations | | | | |
| Economic evidence available to date | | | | |

## 5.0A — Additional supporting evidence
- Clinical practice guidelines / systematic reviews:
- HTA, evidence reviews, and contextual evidence:
- Patient experience, PRO, health-disparity, and quality-measure evidence:
- Other factual supporting information:
- Evidence gaps / unavailable material:

## 6.0A — Dossier appendices
- [ ] References and evidence table
- [ ] Study summaries / protocols / SAPs as permitted
- [ ] Economic-input documentation as permitted
- [ ] Product and administration materials as permitted
- [ ] DTx / technical appendices where relevant
- [ ] Versioned change log and distribution record

## Final internal check
- [ ] Each claim is factual/objective and linked to evidence.
- [ ] Projected information is conspicuously separated from approved/current information.
- [ ] No executive-summary value proposition was added.
- [ ] The complete dossier was reviewed against official AMCP Format 5.0.